NCT00146224View on ClinicalTrials.gov

Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Nephrology
Interventions
DRUG

Epoetin alfa RB

Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.

DRUG

Epoetin alfa DT

Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00146224 - Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis | Biotech Hunter | Biotech Hunter